$BPTH
BIO-PATH HOLDINGS, INC. Stock $bpth

$bpth Overview Financials Valuation SEC Filings Company Website

2015 Q1 Form 10-K Financial Statement

#000114420415016335 Filed on March 16, 2015

Income Statement

Concept	2015 Q1	2014 Q4	2013 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$790.0K	$870.0K	$340.0K
YoY Change	107.89%	155.88%	30.77%
% of Gross Profit
Research & Development	$593.0K	$1.630M	$410.0K
YoY Change	450.91%	297.67%	355.56%
% of Gross Profit
Depreciation & Amortization	$10.00K	$50.00K	$40.00K
YoY Change		25.0%	0.0%
% of Gross Profit
Operating Expenses	$1.379M	$1.603M	$791.0K
YoY Change	170.28%	102.68%	83.94%
Operating Profit	-$1.379M	-$1.603M	-$791.0K
YoY Change	170.28%	102.68%
Interest Expense	$0.00	$10.00K	$0.00
YoY Change	-100.0%
% of Operating Profit
Other Income/Expense, Net	$4.000K	$5.240K	$1.396K
YoY Change	-25.01%	275.36%
Pretax Income	-$1.370M	-$1.600M	-$790.0K
YoY Change	174.0%	102.53%	83.72%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings	-$1.375M	-$1.598M	-$789.6K
YoY Change	172.34%	102.38%	83.62%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$3.044M	-$3.556M	-$1.927M
COMMON SHARES
Basic Shares Outstanding	89.76M shares	89.24M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2015 Q1	2014 Q4	2013 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$12.45M	$13.86M	$3.550M
YoY Change	-25.98%	290.42%	569.81%
Cash & Equivalents
Short-Term Investments
Other Short-Term Assets	$480.0K	$100.5K	$64.12K
YoY Change	204.83%	56.74%	50.6%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$12.94M	$14.11M	$3.667M
YoY Change	-24.88%	284.86%	375.27%
LONG-TERM ASSETS
Property, Plant & Equipment	$102.8K	$113.1K	$0.00
YoY Change
Goodwill
YoY Change
Intangibles	$1.211M	$1.251M	$1.412M
YoY Change	-11.71%	-11.38%	-10.22%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$1.310M	$1.364M	$0.00
YoY Change	-4.47%		-100.0%
TOTAL ASSETS
Total Short-Term Assets	$12.94M	$14.11M	$3.667M
Total Long-Term Assets	$1.310M	$1.364M	$0.00
Total Assets	$14.25M	$15.48M	$5.079M
YoY Change	-23.38%	204.75%	116.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$80.00K	$41.03K	$76.11K
YoY Change	-66.39%	-46.1%	33.52%
Accrued Expenses	$539.7K	$253.4K	$66.74K
YoY Change	584.21%	279.76%	-51.52%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$616.2K	$562.0K	$294.9K
YoY Change	46.74%	90.56%	-10.43%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$616.2K	$562.0K	$294.9K
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$616.2K	$562.0K	$294.9K
YoY Change	46.74%	90.56%	-10.43%
SHAREHOLDERS EQUITY
Retained Earnings		-$19.92M
YoY Change
Common Stock	$89.76K	$89.76K	$84.24K
YoY Change	0.59%	6.56%	35.39%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$13.63M	$14.92M	$4.783M
YoY Change
Total Liabilities & Shareholders Equity	$14.25M	$15.48M	$5.079M
YoY Change	-23.38%	204.75%	116.7%

Cashflow Statement

Concept	2015 Q1	2014 Q4	2013 Q4
OPERATING ACTIVITIES
Net Income	-$1.375M	-$1.598M	-$789.6K
YoY Change	172.34%	102.38%	83.62%
Depreciation, Depletion And Amortization	$10.00K	$50.00K	$40.00K
YoY Change		25.0%	0.0%
Cash From Operating Activities	-$1.410M	-$1.160M	-$470.0K
YoY Change	158.99%	146.81%	11.9%
INVESTING ACTIVITIES
Capital Expenditures		-$50.00K	$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities		-$50.00K	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00
YoY Change	-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	440.0K	-70.00K
YoY Change	-100.0%	-728.57%	-111.11%
NET CHANGE
Cash From Operating Activities	-1.410M	-1.160M	-470.0K
Cash From Investing Activities		-50.00K	0.000
Cash From Financing Activities	0.000	440.0K	-70.00K
Net Change In Cash	-1.410M	-770.0K	-540.0K
YoY Change	-110.63%	42.59%	-357.14%
FREE CASH FLOW
Cash From Operating Activities	-$1.410M	-$1.160M	-$470.0K
Capital Expenditures		-$50.00K	$0.00
Free Cash Flow		-$1.110M	-$470.0K
YoY Change		136.17%	11.9%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q4	us-gaap	Other Inventory OtherInventory	154667	USD
CY2014Q4	us-gaap	Other Assets Current OtherAssetsCurrent	100494	USD
CY2013Q4	us-gaap	Other Inventory OtherInventory	51364	USD
CY2013Q4	us-gaap	Cash Cash	3551832	USD
CY2013Q4	us-gaap	Other Assets Current OtherAssetsCurrent	64117	USD
CY2013Q4	bpth	Authorised Capital To Be Raised AuthorisedCapitalToBeRaised	100000000	USD
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	66739	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	253445	USD
CY2014Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	34743489	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	4783933	USD
CY2013Q4	us-gaap	Liabilities Liabilities	294898	USD
CY2014Q4	us-gaap	Liabilities Liabilities	561971	USD
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	84238	USD
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	89763	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	14113959	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	14916007	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5078831	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	15477978	USD
CY2013Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	20096991	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	294898	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	561971	USD
CY2013	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-1110444	USD
CY2014	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-1550564	USD
CY2014Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	15000000	USD
CY2014Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	13800000	USD
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	89762872	shares
CY2013Q4	us-gaap	Assets Current AssetsCurrent	3667313	USD
CY2013	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	810	USD
CY2014	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	335	USD
CY2012	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	142	USD
CY2013	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3227	USD
CY2012	us-gaap	Net Income Loss NetIncomeLoss	-2582537	USD
CY2013Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	USD
CY2014Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	USD
CY2013	us-gaap	Revenues Revenues	0	USD
CY2014	us-gaap	Revenues Revenues	0	USD
CY2012	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1132712	USD
CY2013Q4	us-gaap	Finite Lived License Agreements Gross FiniteLivedLicenseAgreementsGross	2500374	USD
CY2014Q4	us-gaap	Finite Lived License Agreements Gross FiniteLivedLicenseAgreementsGross	2500374	USD
CY2013Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1088856	USD
CY2014Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1249481	USD
CY2013Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1411518	USD
CY2014Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1250893	USD
CY2013Q4	us-gaap	Assets Assets	5078831	USD
CY2014Q4	us-gaap	Assets Assets	15477978	USD
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	76109	USD
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	41026	USD
CY2013Q4	bpth	Accrued Liabilities Related Parties Current AccruedLiabilitiesRelatedPartiesCurrent	52050	USD
CY2014Q4	bpth	Accrued Liabilities Related Parties Current AccruedLiabilitiesRelatedPartiesCurrent	67050	USD
CY2013Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	100000	USD
CY2014Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	100000	USD
CY2013Q4	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	15397296	USD
CY2014Q4	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	19917245	USD
CY2013Q4	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	76109	USD
CY2014Q4	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	41026	USD
CY2014Q4	us-gaap	Accounts Payable Trade Current And Noncurrent AccountsPayableTradeCurrentAndNoncurrent	38127	USD
CY2014Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	2899	USD
CY2014Q1	bpth	Issuance Of Common Stock And Warrants Shares IssuanceOfCommonStockAndWarrantsShares	5000000	shares
CY2014Q1	bpth	Common Stock Repurchased Shares CommonStockRepurchasedShares	2500000	shares
CY2014Q1	bpth	Issuance Of Common Stock And Warrants Value IssuanceOfCommonStockAndWarrantsValue	15000000	USD
CY2013Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	489501	shares
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	62219050	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	84237872	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	89762872	shares
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	62219050	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	84237872	shares
CY2014Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	4.74
CY2014	us-gaap	Cost Of Reimbursable Expense CostOfReimbursableExpense	75000	USD
CY2014Q4	bpth	Accrued Patent Expense Current AccruedPatentExpenseCurrent	25000	USD
CY2014Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	100000	USD
CY2014Q4	bpth	Accounts Payable And Accrued Liabilities Related Party Current AccountsPayableAndAccruedLiabilitiesRelatedPartyCurrent	167500	USD
CY2014	bpth	Drug Product Testing Agreement Consideration To Be Paid In Stages DrugProductTestingAgreementConsiderationToBePaidInStages	250000	USD
CY2014	bpth	Supply Agreement Consideration To Be Paid In Stages SupplyAgreementConsiderationToBePaidInStages	650000	USD
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2012	us-gaap	Revenues Revenues	0	USD
CY2013	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1518885	USD
CY2014	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1630439	USD
CY2012	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	986097	USD
CY2013	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1634650	USD
CY2014	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2715146	USD
CY2012	us-gaap	Operating Income Loss OperatingIncomeLoss	-2582679	USD
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	-3269240	USD
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	-4542246	USD
CY2012	us-gaap	Investment Income Interest InvestmentIncomeInterest	779	USD
CY2013	us-gaap	Investment Income Interest InvestmentIncomeInterest	4037	USD
CY2014	us-gaap	Investment Income Interest InvestmentIncomeInterest	22632	USD
CY2012	us-gaap	Operating Expenses OperatingExpenses	2582679	USD
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	0	USD
CY2013	us-gaap	Operating Expenses OperatingExpenses	3269240	USD
CY2014	us-gaap	Operating Expenses OperatingExpenses	4542246	USD
CY2012	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	637	USD
CY2014	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	22297	USD
CY2013	us-gaap	Net Income Loss NetIncomeLoss	-3266013	USD
CY2014	us-gaap	Net Income Loss NetIncomeLoss	-4519949	USD
CY2012	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.04
CY2013	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.05
CY2014	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.05
CY2012	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	59317779	shares
CY2013	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	71372672	shares
CY2014	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	89281622	shares
CY2012	us-gaap	Adjustment For Amortization AdjustmentForAmortization	185271	USD
CY2013	us-gaap	Adjustment For Amortization AdjustmentForAmortization	160625	USD
CY2014	us-gaap	Adjustment For Amortization AdjustmentForAmortization	160625	USD
CY2012	us-gaap	Share Based Compensation ShareBasedCompensation	63385	USD
CY2013	us-gaap	Share Based Compensation ShareBasedCompensation	704480	USD
CY2014	us-gaap	Share Based Compensation ShareBasedCompensation	404150	USD
CY2012	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	42000	USD
CY2013	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-143636	USD
CY2014	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	103303	USD
CY2012	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-5864	USD
CY2013	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	21542	USD
CY2014	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	36377	USD
CY2012	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	13113	USD
CY2013	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-34346	USD
CY2014	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	267073	USD
CY2012	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-1993404	USD
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-2313160	USD
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-3817497	USD
CY2012	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
CY2013	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
CY2014	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	123410	USD
CY2012	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-25000	USD
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-123410	USD
CY2012	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1600198	USD
CY2013	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5330946	USD
CY2014	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	13812373	USD
CY2012	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	1600198	USD
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	5330946	USD
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	14247873	USD
CY2012	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	-418206	USD
CY2013	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	3017786	USD
CY2014	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	10306966	USD
CY2011Q4	us-gaap	Cash Cash	952252	USD
CY2012Q4	us-gaap	Cash Cash	534046	USD
CY2012	us-gaap	Interest Paid InterestPaid	0	USD
CY2013	us-gaap	Interest Paid InterestPaid	0	USD
CY2014	us-gaap	Interest Paid InterestPaid	0	USD
CY2012	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2013	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2014	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2012	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2013	us-gaap	Stock Issued1 StockIssued1	771047	USD
CY2014	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2013Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	0	USD
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	123410	USD
CY2013Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	0	USD
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	10284	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	0	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	113126	USD
CY2014	dei	Document Type DocumentType	10-K
CY2014	dei	Amendment Flag AmendmentFlag	false
CY2014	dei	Document Period End Date DocumentPeriodEndDate	2014-12-31
CY2014	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
CY2014	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2014	dei	Entity Registrant Name EntityRegistrantName	BIO-PATH HOLDINGS INC
CY2014	dei	Entity Central Index Key EntityCentralIndexKey	0001133818
CY2014	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2014	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2014	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2014	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2014	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2014Q2	dei	Entity Public Float EntityPublicFloat	248900000	USD
CY2014	dei	Trading Symbol TradingSymbol	BPTH
CY2015Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	89762872	shares
CY2013Q4	us-gaap	Accounts Payable Related Parties Current And Noncurrent AccountsPayableRelatedPartiesCurrentAndNoncurrent	0	USD
CY2014Q4	us-gaap	Accounts Payable Related Parties Current And Noncurrent AccountsPayableRelatedPartiesCurrentAndNoncurrent	100450	USD
CY2012	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-2582537	USD
CY2013	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-3266013	USD
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-4519949	USD
CY2012	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2013	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2014	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2012	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	345000	USD
CY2014	us-gaap	Depreciation Depreciation	10284	USD
CY2012	us-gaap	Depreciation Depreciation	0	USD
CY2013	us-gaap	Depreciation Depreciation	0	USD
CY2013	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	0	USD
CY2014	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	0	USD
CY2012	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	18500	USD
CY2013	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
CY2014	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
CY2012	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	25000	USD
CY2013	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
CY2014	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
CY2012	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2013	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2014	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	435500	USD
CY2014	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	525000	shares
CY2014	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt" align="justify"><strong><i>Concentration of Credit Risk </i></strong> Financial instruments that potentially subject the Company to a significant concentration of credit risk consist of cash. The Company maintains its cash balances with one major commercial bank, JPMorgan Chase Bank. The balances are insured by the Federal Deposit Insurance Corporation up to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">250,000</font>. As a result, as of December 31, 2014, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">13,608,798</font> of the Company’s cash balances were not covered by the FDIC. As of December 31, 2013 the Company had $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,551,832</font> in cash on-hand, of which $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,301,832</font> was not covered by Federal Deposit Insurance Corporation insurance and as of December 31, 2012 the Company had $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">534,046</font> in cash on-hand, of which $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">284,046</font> was not covered by Federal Deposit Insurance Corporation insurance.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	51000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	382000	USD
CY2014	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b><i>Use of Estimates </i></b> The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the Company’s consolidated financial statements and accompanying notes. On an ongoing basis, the Company evaluates its estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that the Company believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from the Company’s estimates.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2014Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	0	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	79000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	81000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	84000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	87000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	3727259	USD
CY2014Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	5025174	USD
CY2012Q4	bpth	Deferred Tax Assets Technology Licenses DeferredTaxAssetsTechnologyLicenses	73021	USD
CY2013Q4	bpth	Deferred Tax Assets Technology Licenses DeferredTaxAssetsTechnologyLicenses	69859	USD
CY2014Q4	bpth	Deferred Tax Assets Technology Licenses DeferredTaxAssetsTechnologyLicenses	66697	USD
CY2014Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	14779928	USD
CY2014	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1530234	USD
CY2012Q3	bpth	Stock Issued During Period Shares Contingent Considerations StockIssuedDuringPeriodSharesContingentConsiderations	50000	shares
CY2014Q1	bpth	Issuance Of Common Stock Shares For Service IssuanceOfCommonStockSharesForService	250000	shares
CY2012Q3	bpth	Issuance Of Common Stock Shares For Service IssuanceOfCommonStockSharesForService	18500	shares
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0078	pure
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0158	pure
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0212	pure
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.85	pure
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.89	pure
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.74	pure
CY2012	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P61M
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P69M
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P80M
CY2012Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Bonuses DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses	39131	USD
CY2013Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Bonuses DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses	15725	USD
CY2014Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Bonuses DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses	48408	USD
CY2012Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	2914697	USD
CY2012Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	383067	USD
CY2013Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	520891	USD
CY2014Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	668611	USD
CY2012Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	179779	USD
CY2013Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	201490	USD
CY2014Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	256568	USD
CY2012Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	3589877	USD
CY2013Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	4535224	USD
CY2014Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	6065458	USD
CY2012Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	3589877	USD
CY2013Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	4535224	USD
CY2014Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	6065458	USD
CY2012Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2013Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2014Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2012	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-878063	USD
CY2012	us-gaap	Income Tax Reconciliation Deductions Extraterritorial Income Exclusion IncomeTaxReconciliationDeductionsExtraterritorialIncomeExclusion	0	USD
CY2013	us-gaap	Income Tax Reconciliation Deductions Extraterritorial Income Exclusion IncomeTaxReconciliationDeductionsExtraterritorialIncomeExclusion	217813	USD
CY2014	us-gaap	Income Tax Reconciliation Deductions Extraterritorial Income Exclusion IncomeTaxReconciliationDeductionsExtraterritorialIncomeExclusion	82333	USD
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	2914974	USD
CY2012	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	179779	USD
CY2013	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	90964	USD
CY2014	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	131722	USD
CY2012	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1056770	USD
CY2013	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	945347	USD
CY2012	us-gaap	Tax Adjustments Settlements And Unusual Provisions TaxAdjustmentsSettlementsAndUnusualProvisions	0	USD
CY2013	us-gaap	Tax Adjustments Settlements And Unusual Provisions TaxAdjustmentsSettlementsAndUnusualProvisions	0	USD
CY2014	us-gaap	Tax Adjustments Settlements And Unusual Provisions TaxAdjustmentsSettlementsAndUnusualProvisions	21439	USD
CY2012	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	1072	USD
CY2013	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	38248	USD
CY2014	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	48280	USD
CY2012	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	63385	USD
CY2013	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	704480	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	404150	USD
CY2012	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	304164	USD
CY2013	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	1397957	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	1187627	USD
CY2012	bpth	Stock Issued During Period Value Previously Sold StockIssuedDuringPeriodValuePreviouslySold	0	USD
CY2014Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	5427778	shares
CY2014	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P6Y
CY2014Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	1.03
CY2014Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	4734861	shares
CY2014Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	0.99
CY2011Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2012Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2013Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2012	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	USD
CY2013	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	USD
CY2014	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	USD
CY2012	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2013	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2014	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2012	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0	USD
CY2013	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0	USD
CY2014	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0	USD
CY2012Q4	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	1572143	USD
CY2013Q4	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	1411518	USD
CY2014Q4	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	1250893	USD
CY2012Q4	us-gaap	Other Finite Lived Intangible Assets Gross OtherFiniteLivedIntangibleAssetsGross	2500374	USD
CY2013Q4	us-gaap	Other Finite Lived Intangible Assets Gross OtherFiniteLivedIntangibleAssetsGross	2500374	USD
CY2014Q4	us-gaap	Other Finite Lived Intangible Assets Gross OtherFiniteLivedIntangibleAssetsGross	2500374	USD
CY2012	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	928231	USD
CY2014Q4	us-gaap	Operating Expenses OperatingExpenses	1603127	USD
CY2013Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-655910	USD
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-510210	USD
CY2013Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-428646	USD
CY2013	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1088856	USD
CY2014	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1249481	USD
CY2014Q4	bpth	Clinical Trial Expense ClinicalTrialExpense	193640	USD
CY2014Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1630439	USD
CY2014	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	435500	USD
CY2014Q4	bpth	Technology Amortisation Period TechnologyAmortisationPeriod	P15Y
CY2014Q4	bpth	Technology Amortisation Monthly TechnologyAmortisationMonthly	160000	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	2014520	USD
CY2014Q4	bpth	Research And Development Costs Expenses ResearchAndDevelopmentCostsExpenses	1630439	USD
CY2014Q4	us-gaap	Adjustment For Amortization AdjustmentForAmortization	160625	USD
CY2014Q4	bpth	Drug Storage And Transportation DrugStorageAndTransportation	11965	USD
CY2014Q4	bpth	Advisory Services AdvisoryServices	90337	USD
CY2014Q4	bpth	Preclinical Studies PreclinicalStudies	40520	USD
CY2014Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	83139	USD
CY2012	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3296354	shares
CY2013	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4848298	shares
CY2014	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4734861	shares
CY2013Q1	us-gaap	Revenues Revenues	0	USD
CY2014Q1	us-gaap	Revenues Revenues	0	USD
CY2013Q2	us-gaap	Revenues Revenues	0	USD
CY2014Q2	us-gaap	Revenues Revenues	0	USD
CY2013Q3	us-gaap	Revenues Revenues	0	USD
CY2014Q3	us-gaap	Revenues Revenues	0	USD
CY2013Q4	us-gaap	Revenues Revenues	0	USD
CY2014Q4	us-gaap	Revenues Revenues	0	USD
CY2013Q1	us-gaap	Operating Expenses OperatingExpenses	655910	USD
CY2014Q1	us-gaap	Operating Expenses OperatingExpenses	510210	USD
CY2013Q2	us-gaap	Operating Expenses OperatingExpenses	428646	USD
CY2014Q2	us-gaap	Operating Expenses OperatingExpenses	1274801	USD
CY2013Q3	us-gaap	Operating Expenses OperatingExpenses	1393728	USD
CY2014Q3	us-gaap	Operating Expenses OperatingExpenses	1154108	USD
CY2013Q4	us-gaap	Operating Expenses OperatingExpenses	790956	USD
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1274801	USD
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1393728	USD
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1154108	USD
CY2013Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-790956	USD
CY2014Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-1603127	USD
CY2013Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-92	USD
CY2014Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	5334	USD
CY2013Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1402	USD
CY2014Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	6024	USD
CY2013Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	521	USD
CY2014Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	5699	USD
CY2013Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1396	USD
CY2014Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	5240	USD
CY2013Q1	us-gaap	Net Income Loss NetIncomeLoss	-656002	USD
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-504876	USD
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	-427244	USD
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	-1268777	USD
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	-1393207	USD
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	-1148409	USD
CY2013Q4	us-gaap	Net Income Loss NetIncomeLoss	-789560	USD
CY2014Q4	us-gaap	Net Income Loss NetIncomeLoss	-1597887	USD
CY2013Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.01
CY2014Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.01
CY2013Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.01
CY2014Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.01
CY2013Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.02
CY2014Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.01
CY2013Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.01
CY2014Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.02
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.37
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.47
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.51
CY2012	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	63385	USD
CY2013	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	704480	USD
CY2014	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	404150	USD
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	914824	USD
CY2012	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	1750	USD
CY2013	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	0	USD
CY2014	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	0	USD
CY2012	bpth	Share Based Compensation Arrangement By Share Based Payment Award Vest And Exercisable Period ShareBasedCompensationArrangementByShareBasedPaymentAwardVestAndExercisablePeriod	Dec-12
CY2013	bpth	Share Based Compensation Arrangement By Share Based Payment Award Vest And Exercisable Period ShareBasedCompensationArrangementByShareBasedPaymentAwardVestAndExercisablePeriod	Dec-13
CY2014	bpth	Share Based Compensation Arrangement By Share Based Payment Award Vest And Exercisable Period ShareBasedCompensationArrangementByShareBasedPaymentAwardVestAndExercisablePeriod	Dec-14
CY2012	bpth	Fund Raising Expense Period FundRaisingExpensePeriod	Dec-12
CY2013	bpth	Fund Raising Expense Period FundRaisingExpensePeriod	Dec-13
CY2014	bpth	Fund Raising Expense Period FundRaisingExpensePeriod	Dec-14
CY2014Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2012	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	USD
CY2013	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	USD
CY2014	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	USD
CY2014	bpth	Stock Options Exercised Issuance Period StockOptionsExercisedIssuancePeriod	Dec-14

Files In Submission

Name	View Source	Status
0001144204-15-016335-index-headers.html	Edgar Link	pending
0001144204-15-016335-index.html	Edgar Link	pending
0001144204-15-016335.txt	Edgar Link	pending
0001144204-15-016335-xbrl.zip	Edgar Link	pending
bpth-20141231.xml	Edgar Link	completed
bpth-20141231.xsd	Edgar Link	pending
bpth-20141231_cal.xml	Edgar Link	unprocessable
bpth-20141231_def.xml	Edgar Link	unprocessable
bpth-20141231_lab.xml	Edgar Link	unprocessable
bpth-20141231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_003.jpg	Edgar Link	pending
image_005.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tex23-1.jpg	Edgar Link	pending
tpg39.jpg	Edgar Link	pending
v404039_10k.htm	Edgar Link	pending
v404039_ex21-1.htm	Edgar Link	pending
v404039_ex23-1.htm	Edgar Link	pending
v404039_ex31.htm	Edgar Link	pending
v404039_ex32.htm	Edgar Link	pending
v404039_ex4-1.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BPTH
BIO-PATH HOLDINGS, INC. Stock $bpth

2015 Q1 Form 10-K Financial Statement

#000114420415016335 Filed on March 16, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BPTH BIO-PATH HOLDINGS, INC. Stock $bpth

2015 Q1 Form 10-K Financial Statement

#000114420415016335 Filed on March 16, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BPTH
BIO-PATH HOLDINGS, INC. Stock $bpth